Inventor · disambiguated record
Arthur M. Brown
Also filed as: BROWN ARTHUR · BROWN ARTHUR M
14 granted patents·24 pending applications·83 citations·filing 1977–2019
90Inventor score
Top patents by PatentIndex Score
38 records- 0186US7700600B2Methods for treating cardiac arrhythmiaCHANTEST INC·Filed 2007·Granted Apr 20, 2010·3 cites·5 claims
- 0284US6743797B2Methods for treating cardiac arrhythmiaCHANTEST INC·Filed 2002·Granted Jun 1, 2004·12 cites·9 claims
- 0380US4128456ASuction electrode for intracellular potential measurementLEE KAI S·Filed 1977·Granted Dec 5, 1978·34 cites·8 claims
- 0469US8187586B2Methods of inducing apoptosis in hyperproliferative cellsBROWN ARTHUR M·Filed 2004·Granted May 29, 2012·2 cites·11 claims
- 0565US2010069403A1Methods for preventing or treating cardiac arrhythmiaBROWN ARTHUR M·Filed 2009·Application pending·0 cites
- 0663US7678548B2High throughput assay systems and methods for identifying agents that alter expression of cellular proteinsCHANTEST INC·Filed 2008·Granted Mar 16, 2010·4 cites·15 claims
- 0763US2004138146A1Methods for preventing or treating cardiac arrhythmiaCHANTEST INC·Filed 2003·Application pending·0 cites
- 0862US6207422B1Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the sameMETROHEALTH SYSTEM·Filed 1998·Granted Mar 27, 2001·19 cites·13 claims
- 0960US11519899B2Metabolomics profiling of central nervous system injuryLONDON HEALTH SCI CT RES INC·Filed 2016·Granted Dec 6, 2022·1 cites·21 claims
- 1058US7060794B2Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the sameMETROHEALTH SYSTEM·Filed 2002·Granted Jun 13, 2006·0 cites·19 claims
- 1156US2016303112A1Methods of remote monitoring of self-administration of vanoxerine for terminating acute episodes of cardiac arrhythmia in mammalsLAGUNA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1255US8450325B2Methods for reducing the recurrence of cardiac arrhythmiaBROWN ARTHUR M·Filed 2011·Granted May 28, 2013·0 cites·5 claims
- 1355US2009143434A1Methods of using domperidone to terminate acute episodes of cardiac arrhythmia, to restore normal sinus rhythm or heart rate, to prevent recurrence of cardiac arrhythmia and to maintain normal sinus rhythm or heart rate in mammalsBROWN ARTHUR M·Filed 2007·Application pending·0 cites
- 1453US6391561B1Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the sameMETROHEALTH SYSTEM·Filed 2000·Granted May 21, 2002·0 cites·10 claims
- 1552US7211407B2High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteinsCHAN TEST INC·Filed 2003·Granted May 1, 2007·3 cites·24 claims
- 1652US2016303114A1Pharmaceutical compositions containing vanoxerine and p450 inhibitors and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythym in mammals through administration of said compositionsLAGUNA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1752US2016303113A1Methods of self-administration of vanoxerine for terminating acute episodes of cardiac arrhythmia in mammalsLAGUNA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1851US2016305924A1Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammalsLAGUNA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1951US2016038482A1Vanoxerine for self-administration for terminating acute episodes of cardiac arrhythmia in mammalsCHANRX CORP·Filed 2014·Application pending·0 cites
- 2050US2015290188A1Pharmaceutical compositions containing enantiomerically pure and/or racemic mixtures of chiral piperazine compounds and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals through administration of said compositionsCHANRX CORP·Filed 2013·Application pending·0 cites
- 2150US2015283131A1Pharmaceutical compositions containing piperazine compounds in combination with a p450 inhibitor and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals through administration of said compositionsCHANRX CORP·Filed 2013·Application pending·0 cites
- 2250US2003083249A1Methods of inducing apoptosis in hyperproliferative cellsFiled 2001·Application pending·0 cites
- 2348US2007259878A1High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteinsCHANXPRESS INC·Filed 2007·Application pending·0 cites
- 2447US2016051541A1Pharmaceutical compositions comprising vanoxerine and antianginal compounds, and methods of administration of the same for treating episodes of cardiac arrhythmia, maintaining normal sinus rhythm, preventing recurrence of cardiac arrhythmia, and treatment of chronic cardiac arrhythmia in mammalsCHANRX CORP·Filed 2014·Application pending·0 cites
- 2546US2023026791A1Peptides, compounds, compositions and methods for inhibiting sox9CRITICAL OUTCOME TECH INC·Filed 2019·Application pending·0 cites
- 2646US2016304477A1Novel metabolites of vanoxerine compounds, pharmaceutical compositions containing the same and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammalsLAGUNA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2745US2005064547A1Vectors and transfected cellsFiled 2003·Application pending·0 cites
- 2844US2015336917A1Novel piperazine compounds, pharmaceutical compositions containing the same and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammalsCHANRX CORP·Filed 2013·Application pending·0 cites
- 2943US2005208595A1High throughput assay systems and methods for identifying agents that alter expression of cellular proteinsBROWN ARTHUR M·Filed 2004·Application pending·0 cites
- 3043US2016051542A1Methods of administration of single doses of vanoxerine to terminate acute episodes of cardiac arrhythmiaCHANRX CORP·Filed 2014·Application pending·0 cites
- 3143US2016051543A1Methods of treatment of cardiac arrhythmias using vanoxerine and modification of dietCHANRX CORP·Filed 2014·Application pending·0 cites
- 3241US8791084B2Inhibition of SOX9 function in the treatment of proteoglycan-associated pathophysiological conditionsBROWN ARTHUR·Filed 2007·Granted Jul 29, 2014·0 cites·6 claims
- 3339US2005054010A1High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteinsFiled 2003·Application pending·0 cites
- 3438US5733889ATreatment for cardiac arrhythmiasMETROHEALTH SYSTEM·Filed 1996·Granted Mar 31, 1998·5 cites·10 claims
- 3538US2013266663A1Sox9 inhibitorsBROWN ARTHUR·Filed 2011·Application pending·0 cites
- 3636US11873340B2Anti-CD11D antibodies and uses thereofUNIV WESTERN ONTARIO·Filed 2017·Granted Jan 16, 2024·0 cites·18 claims
- 3733US2012028992A1Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammalsBROWN ARTHUR M·Filed 2010·Application pending·0 cites
- 3832US2012010216A1Pharmaceutical compositions containing vanoxerineBROWN ARTHUR M·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Arthur M. Brown files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →